AXGN Axogen, Inc.
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.…
Industry Peers
Medical DevicesKey Statistics
About Axogen (NASDAQ: AXGN)
›
Axogen (NASDAQ: AXGN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 622 employees.
The shares were at 56.35 USD on 19 November 2026, up 134.9% over 52 weeks. Its 52-week range is 23.00 USD to 59.72 USD: the price is 5.6% below the high and 145.0% above the low.
Its market capitalisation is 3.37B USD.
Axogen reports return on equity of -12.2%, an operating margin of -5.2% and revenue up 26.2% year over year.
It holds more cash than debt, a net cash position of 328.60M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 59.27 USD is 5.2% above the current price. The next earnings report is expected on 23 February 2027.